VERA (Vera Therapeutics) ROC %: -5,830.26% (As of Mar. 2026)


VERA Vera Therapeutics Inc VERA
34 GF Score
Price $39.89
! 3 Warning Signs
View Full Analysis

What is Vera Therapeutics ROC %?

Vera Therapeutics VERA +0.96% 34 ROC % is -5,830.26% as of Mar. 2026. GuruFocus rates VERA with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Vera Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -5,830.26%.

As of today (2026-06-25), Vera Therapeutics's WACC % is 19.84%. Vera Therapeutics's ROC % is -5160.87% (calculated using TTM income statement data). Vera Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Vera Therapeutics  (NAS:VERA) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Vera Therapeutics's WACC % is 19.84%. Vera Therapeutics's ROC % is -5160.87% (calculated using TTM income statement data). Vera Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Vera Therapeutics ROC % Related Terms


Vera Therapeutics ROC % Historical Data

* Premium members only.

The historical data trend for Vera Therapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vera Therapeutics ROC % Chart

Vera Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial -2,420.12 -1,823.53 -1,422.66 -2,447.94 -4,079.83

Vera Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,524.78 -4,816.53 -4,569.59 -5,222.42 -5,830.26
VERA
34GF Score
Vera Therapeutics Inc VERA
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vera Therapeutics ROC % Calculation

Vera Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-315.473 * ( 1 - -0% )/( (7.6990000000001 + 7.766)/ 2 )
=-315.473/7.7325
=-4,079.83 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=655.681 - 22.135 - ( 640.852 - max(0, 25.371 - 651.218+640.852))
=7.6990000000001

Vera Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-500.528 * ( 1 - 0% )/( (7.766 + 9.404)/ 2 )
=-500.528/8.585
=-5,830.26 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -5,830.26% mean?
Vera Therapeutics (VERA) has a ROC % of -5,830.26% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Vera Therapeutics and its competitors.
Is Vera Therapeutics' ROC % too high?
Vera Therapeutics' current ROC % is -5,830.26%. Overall, Vera Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Vera Therapeutics' ROC % compare to TARS and IDYA?
Vera Therapeutics' ROC % of -5,830.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Vera Therapeutics and its competitors. Vera Therapeutics's current ROC % is -5,830.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vera Therapeutics stock overvalued right now?
Vera Therapeutics (VERA) has a current ROC % of -5,830.26%. The current ROC % is -5,830.26%. Vera Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Vera Therapeutics (VERA), the current ROC % is -5,830.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vera Therapeutics Business Description

Address 2000 Sierra Point Parkway, Suite 1200, Brisbane, CA, USA, 94005
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
34GF Score

Get the complete analysis for VERA

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.89
Price